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AMYLOID PEPTIDE INACTIVATING 
ENZYME TO TREAT ALZHEIMER'S 
DISEASE PERIPHERALLY 
RELATED APPLICATIONS 
This application is a national phase of PCT/US2005/ 
030396 which claims priority from U.S. Provisional Appli-
cation No. 60/604,700 filed Aug. 27, 2004, the disclosures of 
which Applications are incorporated by reference herein. The 
benefit of the filing and priority dates of the International and 
U.S. Applications is respectfully requested. 
GOVERNMENT INTEREST IN THE INVENTION 
2 
can reduce the number of preformed amyloid plaques (Marr, 
R. A. eta!. (2003) Neprilysin gene transfer reduces amyloid 
pathology in mouse models of Alzheimer's disease. J. Neuro-
sci. 23:1992-1996). This is the first report that shows that 
5 neprilysin can actually be used to "dissolve" preformed 
plaques. Since neprilysin does not degrade aggregated A~, 
this demonstrates that the aggregated A~ must be in a 
dynamic equilibrium with free A~ or small A~ oligomers. We 
have also conducted preliminary experiments designed to test 
10 the effect of neprilysin expression in the brain of an hAPP 
mouse model as a way to degrade A~ and prevent amyloid 
deposits from forming. As shown in FIG. 3, we found that 
using the lentivirus-neprilysin construct to express neprilysin 
in the hippocampus of the 120 human hAPP transgenic mouse 
15 model of AD, virtually eliminated amyloid deposits in the 
9-month old mouse. (Id.). In the lentivirus-NEP treated brain 
(FIG. 3B, right) there is a small amount of diffuse light 
staining material, indicative of amyloid peptide, as compared 
This invention was made with Government support under 
four grants: (1) grant no. UKRF#465181 awarded by the 
Alzheimer's Association, (2) grant no. DA02243 awarded by 
the National Institute on Drug Abuse, (3) grant no. AG19323 
awarded by the National Institute on Aging, and ( 4) grant no. 20 
AG024899 also awarded by the National Institute on Aging. 
The Government has certain rights in this invention. 
to the controllentivirus-GFP (FIG. 3A, right). (Id.). 
More recently interest has emerged in targeting the clear-
ance of A~ peptides as a therapeutic approach, primarily 
through the use of antibodies to A~. This approach involves 
either immunizing with A~ (Schenk D, eta!. (1999) Immuni-
zation with amyloid-~ attenuates Alzheimer-disease-like FIELD OF THE INVENTION 
The present invention relates to methods of and transduced 
stem cells and modified peptidase for preventing amyloid 
peptide (A~) accumulation, and plaque formation in the brain 
by raising amyloid peptide inactivating enzyme activity in the 
periphery. The present invention also relates to methods of 
lowering plasma A~ levels as a way to lower brain A~ using 
expression of amyloid peptide inactivating enzymes, like 
neprilysin, on hematopoietic cells. The present invention also 
relates to a method of treating and/ or preventing Alzheimer's 
disease. 
BACKGROUND OF THE INVENTION 
The incidence of Alzheimer's disease (AD) is estimated to 
currently affect up to 4 million Americans and this number 
will certainly increase as our population continues to age. 
Approximately 3% of the population between ages 65 to 74 
suffer from AD, and this value increases with increasing age. 
Since AD patients generally live 8 to 10 years after the disease 
is diagnosed, the financial burden AD imposes on our 
economy is estimated to exceed $100 billion and will con-
tinue to increase. Although there are a number of acetylcho-
linesterase inhibitors as approved drugs that can improve the 
symptoms of AD patients over the short term, no current 
therapy can retard disease progression. It is widely accepted 
that the oligomerization and subsequent deposition of amy-
loid~ peptides (A~) is a major factor in AD. Thus consider-
able effort has been expended in the development of drugs 
that can selectively inhibit the ~ andy secretases responsible 
for A~ formation. To date no such drugs have reached the 
marketplace. 
In recent years attention has been given to the peptidases 
that are involved in amyloid peptide (e.g., A~) clearance, such 
as neprilysin and insulysin. It has been shown that inhibition 
25 pathology in the PDAPP mouse. Nature 400:173-177; Janus 
C, et a!. (2000) A peptide immunization reduces behavioral 
impairment and plaques in a model of Alzheimer's disease. 
Nature 408:979-982; Morgan D et a!. (2000) A~ peptide 
vaccination prevents memory loss in an animal model of 
30 Alzheimer's disease. Nature 408:982-985; Weiner H L, eta!. 
(2000) Nasal administration of amyloid-~ peptide decreases 
cerebral amyloid burden in a mouse model of Alzheimer's 
disease.AnnNeurol48:567-579; Das P, eta!. (2001)Reduced 
effectiveness of A~ 1-42 immunization inAPP transgenic mice 
35 with significant amyloid deposition. Neurobiol Aging 
22:721-727) or through the passive administration of A~ anti-
bodies (Bard F, et a!. (2000) Peripherally administered anti-
bodies against amyloid ~-peptide enter the central nervous 
system and reduce pathology in a mouse model of Alzheimer 
40 disease. Nat Med 6:916-919; DeMattos R B, eta!. (2001) 
Peripheral anti-A~ antibody alters CNS and plasma A~ clear-
ance and decreases brain A~ burden in a mouse model of 
Alzheimer's disease. Proc NatlAcad Sci USA 98:8850-8855; 
DeMattos R B, eta!. (2002)Brain to plasma amyloid-~ efflux: 
45 a measure of brain amyloid burden in a mouse model of 
Alzheimer's disease. Science 295:2264-2267). The promis-
ing results derived from A~ immunization studies in mice led 
to clinical trials using A~ immunization that initially 
appeared to produce beneficial results (Hock C, eta!. (2003) 
50 Antibodies against beta-amyloid slow cognitive decline in 
Alzheimer's disease. Neuron. 38:547-54). However, several 
patients developed encephalitis (Greenberg S M, eta!. (2003) 
Alzheimer disease's double-edged vaccine. Nat Med. 9:389-
390) and the clinical trails were stopped. Consequently there 
55 exists a need to safely and effectively treat Alzheimer's dis-
ease. 
or deletion of these peptidases in rodent models leads to 60 
elevated A~, and that introduction of these peptidases into the 
brain of transgenic mice expressing human amyloid precur-
sor protein (hAPP) can lead to a reduction inA~ levels (Leis-
sring M A, et a!. (2003). Enhanced proteolysis of beta-amy-
loid in APP transgenic mice prevents plaque formation, 65 
secondary pathology, and a premature death. Neuron 40, 
1087-1 093). In addition expression of neprilysin in the brain 
One of the theories that immerged from the immunological 
studies was that passive immunization with A~ antibodies 
resulted in an efflux of A~ from the brain into the plasma 
producing a peripheral "sink effect", DeMattos eta!., 2001, 
2002. It has been shown that peripheral administration of an 
anti-A~ monoclonal antibody resulted in a rapid 1,000 fold 
increase in plasma A~ and a marked reduction in A~ deposi-
tion in the brain, DeMattos eta!., 2001. Subsequently, it was 
shown that introduction of two A~-binding compounds, gan-
glioside GM1 and gelsolin, to bind plasma A~ in hAPP trans-
genic mice, resulted in a lowering of brain A~ levels by 50% 
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or more (Matsuoka Y, et a!. (2003) Novel therapeutic 
approach for the treatment of Alzheimer's disease by periph-
eral administration of agents with an affinity to beta-amyloid. 
4 
J Neurosci, 23:29-33). In this study it was demonstrated that 
the lowering of brain A~ by ganglioside GMl was not due to 
ganglioside GMl crossing the blood-brain barrier. It has also 
been shown that exogenous A~ is rapidly transported from the 
CSF to plasma, exhibiting a half-time of -30 min (Ghersi-
Egea J F, eta!. (1996) Fate of cerebrospinal fluid-borne amy-
loid beta-peptide: rapid clearance into blood and appre- 10 
ciable accumulation by cerebral arteries. J Neurochem. 
67:880-883; Shibata M, et a!. (2000) Clearance of Alzhe-
imer's amyloid-ss(l-40) peptide from brain by LDL receptor-
related protein-] at the blood-brain barrier. J Clin Invest. 15 
106: 1489-99). Yet another example is to use a soluble recep-
In another preferred embodiment, there is a method of 
reducing amy laid peptide in the brain comprising inactivating 
peripheral amyloid peptide by peripheral expression of amy-
loid peptide inactivating enzyme comprising the steps of: 
a. generating a recombinant viral or plasmid vector com-
prising a nucleotide sequence encoding an amyloid peptide 
inactivating enzyme operatively linked to a promoter; and 
b. introducing the vector into hematopoietic stem cells in 
vivo by injection, such that the amyloid peptide inactivating 
enzyme is expressed on the surface of or secreted from 
hematopoietic cells, 
In another aspect of the present invention, there are trans-
duced stem cells for treating and/or preventing Alzheimer's 
disease. In a preferred embodiment stem cells are transduced 
with a vector encoding an amyloid peptide inactivating 
tor for advanced glycation end products (RAGE) in the blood 
to bind A~ (DeaneR. eta!. (2003)RAGE mediates amyloid-~ 
peptide transport across the blood-brain barrier and accu-
mulation in brain. Nat. Med. 9, 907-913). 
enzyme. Preferably the stem cells are hematopoietic stem 
cells. In a preferred embodiment the vector is a viral vector, 
and most preferably a lentivirus or adena associated viralvec-
20 tor. In a preferred embodiment the amyloid peptide inactivat-
ing enzyme is a peptidase, and most preferably, the peptidase 
is neprilysin or a biologically active derivative or fragment 
thereof. 
The present invention comprises methods of lowering 
plasma A~ levels as a way to lower brain A~ using peripheral 
expression of amyloid peptide inactivating enzymes, like 
neprilysin, on hematopoietic cells. The methods a flowering 
plasma A~ comprise i) peripheral expression of an amyloid 25 
peptide inactivating enzyme in hematopoietic stem cells com-
prising a viral vector to infect bone marrow stem cells with a 
neprilysin-expressing or other A~-degrading peptidase-ex-
pressing construct; ii) coupling of neprilysin or other A~ 
degrading peptidases to hematopoietic cells; iii) modifying 30 
amyloid peptide inactivating enzymes such that the enzyme 
will bind to hematopoietic cells; or iv) use of liposomes or 
other agents to introduce neprilysin or other A~ degrading 
peptidases into hematopoietic cells. 
In another aspect of the invention, there is a method of 
reducing amy laid peptide in the brain comprising inactivating 
peripheral amyloid peptide by coupling amyloid peptide 
inactivating enzymes to hematopoietic cells. In a preferred 
embodiment, method comprises the steps of: 
a. taking a sample of hematopoietic cells from a patient; 
b. coupling one or more hematopoietic cells to one or more 
amyloid peptide inactivating enzyme ex vivo; and 
c. introducing the amyloid peptide inactivating enzyme-
bound-hematopoietic cells into the blood of the patient; 
Coupling may be performed by one of several methods. 
SUMMARY OF THE INVENTION 
The present invention addresses the need for a method of 
preventing and treating Alzheimer's disease by inactivating 
peripheral amyloid peptide. 
In one aspect of the present invention, there is a method for 
the reducing amyloid peptide in the brain of a mammalian 
host comprising inactivating peripheral amyloid peptide by 
peripherally expressing an effective amount of an amyloid 
peptide inactivating enzyme to reduce, via efflux, amyloid 
peptide from the brain. Peptidase is a preferred amyloid pep-
tide inactivating enzyme used in the aspects and embodi-
ments of this invention. The peptidase may be introduced by 
ex vivo or in vivo techniques known by one of ordinary skill 
in the art. 
In a preferred embodiment, the invention provides a 
method for reducing amyloid peptide in the brain comprising 
inactivating peripheral amyloid peptide by peripheral expres-
sion of amyloid peptide inactivating enzymes comprising the 
steps of: 
a. generating a recombinant viral or plasmid vector com-
prising a nucleotide sequence encoding an amyloid peptide 
inactivating enzyme; 
b. taking a sample of hematopoietic stem cells from a 
patient; 
c. introducing ex vivo the recombinant viral or plasmid 
vector into one or more hematopoietic stem cells of the 
sample; and 
d. transplanting the hematopoietic stem cells of step c. into 
the patient, such that the amyloid peptide inactivating enzyme 
is expressed on the surface of hematopoietic cells or secreted 
from hematopoietic cells, 
35 Preferably, the coupling is facilitated by biotinylation of the 
enzyme and the hematopoietic cells using streptavidin and/or 
avidin to couple biotin-bound molecules together. In another 
preferred method coupling is facilitated by chemical cross-
40 
linking reagents such as glutaraldehyde. 
In another preferred embodiment the coupling is effected 
by modifying one or more enzyme so that it binds to one or 
more hematopoietic cell. Modification preferably includes 
coupling a C-terminal human red blood cell binding peptide 
sequence to amyloid peptide inactivating enzyme such that 
45 the C-terminal human RBC binding peptide sequence-bound 
enzyme couples with one or more hematopoietic cells. Modi-
fication also preferably includes coupling an antibody to 
hematopoietic cells to an amyloid peptide inactivating 
enzyme such that the antibody-bound enzyme couples with 
so one or more hematopoietic cells. Modification also prefer-
ably includes coupling the C-terminal red blood cell binding 
peptide sequence to the enzyme, or coupling an antibody to 
hematopoietic cells to the enzyme. Modification also prefer-
ably includes adding an anchor, such as glycoinositol phos-
55 pholipid (GPI), to an amyloid inactivating enzyme to permit 
insertion of the amyloid peptide inactivating enzyme into the 
membrane of a hematopoietic cell. 
In another preferred aspect of the present invention, there is 
a method of reducing amyloid peptide in the brain comprising 
60 modifYing in vitro one ore more amyloid peptide inactivating 
enzyme such that the modified amyloid peptide inactivating 
enzymes binds to one or more hematopoietic cells and intro-
ducing the one or more modified amy laid peptide inactivating 
enzyme coupled hematopoietic cells into the blood of a 
65 patient. Modification of the amyloid peptide inactivating 
enzyme comprise the methods disclosed herein and others 
that are known or become known to one skilled in the art of 
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coupling molecules, preferably, coupling amyloid peptide 
inactivating enzymes to hematopoietic cells. 
In still another aspect of the invention, there is a method of 
reducing amyloid peptide in the brain comprising inactivating 
peripheral amyloid peptide by introducing an amyloid pep-
tide inactivating enzyme into hematopoietic cells of a patient 
via liposomes or other delivery reagents. The amyloid peptide 
inactivating enzyme-containing liposome may be delivered 
ex-vivo into the hematopoietic cells of a patient and then 
transplanted into a patient or delivered in vivo into the 10 
hematopoietic cells of a patient. 
It is yet another aspect of the invention to provide methods 
for preventing and/or treating a patient with Alzheimer's dis-
ease utilizing the methods described herein to reduce levels or 15 
prevent accumulation of amyloid peptide in the brain. In one 
preferred embodiment, the method comprises administering 
(ex vivo or in vivo) to the hematopoietic stem cells of a patient 
6 
0.1% cells appearing as CD45.1 +cells. This illustrates that 
bone marrow cells can be transplanted from a donor to a 
recipient. 
FIGS. 5 (A and B) illustrates the flow cytometric analysis 
of hematopoietic bone marrow cells from a bone marrow 
transplant recipient mouse for neprilysin expression (NEP) 
and inactive neprilyisn (NEPx) compared to an untreated 
mouse. 
FIG. SA shows the ability to transplant NEP-lentivirus 
transduced bone marrow cells from a donor to a recipient 
mouse: Left-a histogram of lentivirus-NEP-transduced 
bone marrow stem cells from a donor mouse transplanted to a 
recipient mouse; Center-a histogram of a recipient mouse 
without bone marrow transplantation; and Right-a histo-
gram of a recipient mouse after bone marrow transplantation 
without treatment with FITC conjugated anti-NEP antibody. 
FIG. 5 B shows data in a repeat of the experiment. The 
NEP-lentivirus was used to transduce bone marrow stem cells 
20 from a donor mouse, which were transplanted into a two-
month old recipient mouse to produce neprilysin expression 
on white blood cells. About 65% of the bone marrow cells 
used for transplantation expressed neprilysin. Cells in the M1 
in need thereof a therapeutically effective amount of a recom-
binant viral vector or plasmid vector comprising a nucleotide 
sequence encoding an amyloid peptide inactivating enzyme 
operatively linked to a promoter such that it is expressed on 
the surface of or secreted from hematopoietic cells. In another 
preferred embodiment, a therapeutically effective amount of 
stem cells transduced with a DNA vector encoding an amy- 25 
laid peptide inactivation enzyme are administered to a 
patient. In another preferred embodiment, the method com-
prises administering to a patient in need thereof a therapeu-
tically effective amount of an amyloid peptide inactivating 
enzyme to peripheral hematopoietic cells by the methods 30 
described herein to inactivate peripheral amyloid peptide 
resulting in a reduction, via efflux, of amyloid peptide from 
the brain. 
These and other aspects of the invention will be more fully 
understood from the following description of the invention 35 
and the referenced drawings attached hereto. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 illustrates a lentiviral virus construct used for 40 
expression of neprilysin on hematopoietic cells. Similar con-
structs can be used for expressing other A~ degrading 
enzymes. 
FIG. 2 illustrates that the expression of neprilysin (NEP) in 
A~ secreting CHO cells (7PA2) efficiently reduces A~ in the 45 
media. NEPx is an inactive point mutant of neprilysin on the 
cell surface. SecNEP is an engineered secreted form of nepril-
ysin. NEP is wild type neprilysin on the cell surface. 
region are neprilysin positive cells. Control is a histogram of 
a recipient mouse without bone marrow transplantation. 
There are less than 2% cells appearing as neprilysin positive 
cells. The panel labeled NEP is a histogram of cells from a 
recipient mouse receiving NEP-lentivirus transduced bone 
marrow cells and shows greater than 20% of the white blood 
cells express neprilysin. The panel labeled NEPx is a histo-
gram of cells from a recipient mouse receiving inactive NEP-
lentivirus transduced bone marrow cells and shows greater 
than 20% of the white blood cells express inactive neprilysin 
FIG. 6 shows reduced A~ in the brain from NEP peripher-
ally expressed on white blood cells. 
FIG. 7 shows reduced amyloid deposits in the brain of an 
hAPP transgenic mouse in the brain from NEP peripherally 
expressed on white blood cells. 
FIG. 8 (A-B) illustrates lentiviral virus constructs for 
expression of neprilysin on red blood cells. Similar constructs 
can be used for expressing other A~ degrading enzymes. 
FIG. 9 shows the time course of NEP biotinylation with 
biotin-N -hydroxysuccinimide 
FIG. 10 shows that biotinylated NEP (as shown in FIG. 9) 
retains enzymatic activity. 
FIG. 11 shows that red blood cells can be biotinylated. 
FIG. 12 shows that biotinylated NEP can be linked to 
biotinylated red blood cells through streptavidin. 
FIG. 13 shows a modified form of neprilysin in which a 
C-terminal human red blood cell binding peptide sequence is 
attached. SS represents a secretion signal. 
FIG. 3 illustrates A~ deposits in the 9-month control (len-
tivirus-GFP) (FIG. 3A, left) or lentivirus-NEP transduced 50 
(FIG. 3B, right) 120 hAPP transgenic mouse. The arrows 
indicate A~ deposits, which are numerous and dense in the 
control virus treated mouse. In the lentivirus-NEP treated 
brain there is a small amount of diffuse light staining material. 
FIG. 4 (A-C) illustrates the flow cytometric analysis of a 
bone marrow transplanted recipient mouse (CD45.2+) for 
expression of donor-specific lenkocyte common antigen vari-
ant CD45 .1. Panel A is a histogram of a recipient mouse's 
white blood cells 30 days after bone marrow transplantation. 
FITC conjugated anti CD45.1 antibody A20 (PharMingen) 60 
was used. Cells in the M1 region are CD45 .1 +donor cells and 
represent about 30% of the total cells. Panel B is a histogram 
FIG. 14 shows that modified neprilysin containing a C-ter-
minal human red blood cell binding peptide sequence is 
55 bound to red blood cells. 
of the same recipient mouse's white blood cells as in the left 
panel, but without FITC conjugated anti CD45.1 antibody. 
There are less than 0.1% cells appearing as CD45.1 positive 65 
cells, while panel C is a histogram of a recipient mouse 
without bone marrow transplantation. There are less than 
FIG. 15 shows a modified form of neprilysin in which a 
C-terminal single chain antibody directed against a red blood 
cell surface epitope sequence is attached. 
DETAILED DESCRIPTION 
All patents, patent applications and literature cited in this 
description are incorporated in their entirety by reference 
herein. In the case of inconsistencies, the present disclosure, 
including definitions, will prevail. 
As used herein, an "amyloid peptide" includes beta or 
gamma amyloid peptides (i.e.,A~ andAy, respectively). Pref-
US 9,044,503 B2 
7 
erably, the peptide is amyloid beta peptide. More preferably, 
the beta peptide isA~ 1 _40 or A~ 1 _42 . Most preferably, the beta 
peptide is A~ 1 _42 . 
As used herein, an "amyloid peptide inactivating enzyme" 
encompasses a group of functionally or structurally related 
proteins that modulate, bind to, and/or hydrolyze amyloid 
peptides, and prevent the peptides from depositing as plaques 
or fibrils. Preferably, toxic side-effects are minimized. By 
"inactivating" it is meant that the enzyme may functionally 
prevent amyloid peptides from aggregating and from forming 10 
plaques. Preferably, "inactivating" refers to degrading, clear-
ing and/or dissolution of the amyloid peptide, plaque or fibril. 
Preferably "degrading" or "clearing" refers to the act of 
changing a protein, like A~, or a protein complex, like amy- 15 
laid plaques and fibrils, to a less complex protein or protein 
complex, respectively. Degradation of A~ is preferably by 
hydrolysis, a chemical process whereby a compound is 
cleaved into two or more simpler compounds with the uptake 
of the Hand OH parts of a water molecule on either side of the 20 
chemical bond cleaved (e.g., insulysin as shown in U.S. Pub-
lished Patent Application No. 2003/0165481). Degradation 
of A~ plaques may be caused by an equilibrium between 
fibrillary A~ and monomeric, dimeric or trimeric A~, the 
monomeric, dim eric and trim eric forms of A~ are hydrolyzed 25 
by neprilysin (Kanemitsu H, Tomiyama T, Mori H. (2003) 
Human neprilysin is capable of degrading amyloid beta pep-
tide not only in the monomeric form but also the pathological 
oligomeric form. Neurosci Left. 350: 113-116) thus "pulling" 
theA~ out of the plaque through equilibration with the mono- 30 
mer or low molecular oligomers and leading to a dissolution 
of the plaque. Preferably, the enzyme is a peptidase. Non-
limiting examples of the enzyme include insulysin (also 
known as insulin degrading enzyme or IDE), neprilysin (also 
known to as endopeptidase 24.11, NEP, or CALLA), nepril- 35 
ysin 2 (also known as secreted endopeptidase, secNEP, or 
membrane metallo-endopeptidase-like 2), endopeptidase 
24.15 (also known as thimet oligopeptidase 1 ), endopeptidase 
24.16 (also known as neurolysin), endothelin converting 
enzyme, angiotensin converting enzyme (also known as 40 
dipeptidase A), plasmin, MMP-9 (also known as gelatinase 
B), or similar peptidases or a combination thereof. 
As used herein, the terms "bind" or "link," or "binds" or 
"links", or "binding" or "linking" means any interaction 
between two or more molecules by covalent or noncovalent 45 
forces, Van der waals forces, electrostatic forces, and/or 
hydrostatic forces. 
As used herein, the term "biologically active" in reference 
to a nucleic acid, protein, protein fragment or derivative 
thereof is defined as an ability of the nucleic acid or amino 50 
acid sequence to mimic a known biological function elicited 
by the wild type form of the nucleic acid or protein. 
As used herein, the terms "coupling" or "coupled" or 
"couple" means any interaction, association with, attach-
ment, conjugation, linking, or binding of one molecule (in- 55 
eluding compounds, labels and ligands, amino acid sequence, 
or nucleic acid sequence) to another molecule, by direct or 
indirect means, using reactive groups, either in the molecules 
per se or in a chemical or molecule added for that purpose, in 
such a way as to allow each of the molecules to function in 60 
their intended manners. 
As used herein, the term "expression" means the detectable 
effect of a gene, like a nucleic acid sequence encoding a 
peptidase or biologically active derivative or fragment. The 
term "express" means to manifest the detectable effect of a 65 
gene. A gene may be expressed inside a cell, on the surface of 
a cell or be secreted by the cell. 
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As used herein, the terms "hematopoietic" and "hemopoi-
etic" are used interchangeably and mean pertaining to or 
relating to the formation of blood cells. 
As used herein, the terms "hematopoietic cells" and 
"hemopoietic cells" are used interchangeably herein and refer 
to any cell pertaining to or relating to the blood, including 
white blood cells (WBCs) that fight infection and inflamma-
tions (e.g., leukocytes, lymphocytes), red blood cells (RBCs) 
that carry oxygen (e.g., erythrocytes), and platelets that are 
responsible for blood clotting. 
As used herein, "hematopoietic stem cell(s)", "hemopoi-
etic stem cells", "hematopoietic progenitor cell(s)" and 
"hemopoietic progenitor cell(s)" are used interchangeably 
herein and refer to any precursor cell whose daughter cells 
may differentiate into various cells that are found in mamma-
lian blood systems, including, white blood cells that fight 
infection and inflammations (e.g., leukocytes, lymphocytes), 
red blood cells that carry oxygen (e.g., erythrocytes), and 
platelets that are responsible for blood clotting. 
As used herein, the term "inactivate" refers to the act of 
degrading, clearing and/or dissolving A~ from the periphery 
or the central nervous system. 
As used herein, the term "maintenance", when used in the 
context of delivery to hematopoietic stem cells, denotes the 
ability of introduced DNA to remain present in the cell. When 
used in other contexts, it means the ability of targeted DNA to 
remain present in the targeted cell or tissue so as to impart a 
therapeutic effect. 
As used herein, the term "mammalian host" includes mem-
bers of the animal kingdom including but not limited to 
human beings. 
As used herein, the term "operatively linked" refers to the 
linkage of a DNA segment to another DNA segment in such 
a way as to allow the segments to function in their intended 
manners. A DNA sequence encoding a gene product is opera-
tively linked to a regulatory sequence when it is ligated to the 
regulatory sequence, such as, for example, promoters, 
enhancers and/or silencers, in a manner which allows modu-
lation of transcription of the DNA sequence, directly or indi-
rectly. For example, a DNA sequence is operatively linked to 
a promoter when it is ligated to the promoter downstream 
with respect to the transcription initiation site of the promoter, 
in the correct reading frame with respect to the transcription 
initiation site, and allows transcription elongation to proceed 
through the DNA sequence. An enhancer or silencer is opera-
tively linked to a DNA sequence coding for a gene product 
when it is ligated to the DNA sequence in such a manner as to 
increase or decrease, respectively, the transcription of the 
DNA sequence. Enhancers and silencers may be located 
upstream, downstream or embedded within the coding 
regions of the DNA sequence. A DNA for a signal sequence is 
operatively linked to DNA coding for a polypeptide if the 
signal sequence is expressed as a preprotein that participates 
in the secretion of the polypeptide. Linkage of DNA 
sequences to regulatory sequences is typically accomplished 
by ligation at suitable restriction sites or via adapters or link-
ers inserted in the sequence using restriction endonucleases 
known to one of skill in the art. 
As used herein, the term "patient" includes members of the 
animal kingdom including but not limited to human beings. 
As used herein, the term "peripheral" or "periphery" means 
relating to the outside of, or being situated outside of, the 
central nervous system. 
As used herein, a "promoter" can be any nucleotide 
sequence that is active, and controls transcription in a eukary-
otic cell. The promoter may be active in either or both eukary-
otic and prokaryotic cells. Preferably, the promoter is active 
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in mammalian cells. Most preferably, the promoter is active in 
mammalian hematopoietic cells. The promoter may be con-
stitutively expressed or inducible. 
As used herein, a "selectable marker" includes a gene 
product that is expressed by a cell that stably maintains the 
introduced DNA, and causes the cell to express an altered 
phenotype such as morphological transformation, or an enzy-
matic activity. Isolation of cells that express a transfected 
gene is achieved by introduction into the same cells a second 
gene that encodes a selectable marker, such as one having an 
enzymatic activity that confers resistance to an antibiotic or 
other drug. Examples of selectable markers include, but are 
not limited to, thymidine kinase, dihydrofolate reductase, 
aminoglycoside phosphotransferase, which confers resis-
tance to amino glycoside antibiotics such as kanamycin, neo-
mycin and geneticin, hygromycin B phosphotransferase, xan-
thine-guanine phosphoribosyl transferase, CAD (a single 
protein that possesses the first three enzymatic activities of de 
novo uridine biosynthesis--carbamyl phosphate synthetase, 
aspartate transcarbamylase and dihydroorotase ), adenosine 
deaminase, and asparagine synthetase (Sambrook et a!. 
Molecular Cloning, Third Edition Chapter 16. 2001), incor-
porated in its entirety by reference herein. 
As used herein, the terms "stem cell(s)" and "progenitor 
cell( s )"are used interchangeably and mean any precursor cell 
whose daughter cells may differentiate into other cell types. 
As used herein, the term "therapeutically effective 
amount" means an amount sufficient to inactivate amyloid 
peptide in the periphery and/or the central nervous system. 
In one aspect the present invention discloses ex vivo and in 
vivo techniques for delivery and expression of a DNA 
sequence of interest to the periphery of a mammalian host. 
One of the ex vivo techniques involves culture of cells, in vitro 
transfection of the DNA sequence, DNA vector or other deliv-
ery vehicle of interest into the cells, followed by transplanta-
tion of the modified cells to the target joint of the mammalian 
host, so as to effect in vivo expression of the gene product of 
interest. 
It will be understood by the artisan of ordinary skill that the 
preferred source of cells for treating a human patient is the 
patient's own tissues, such as autologous bone marrow, and 
preferably autologous hematopoietic stem cells. Hematopoi-
etic stem cells may differentiate to white cells (e.g., leuko-
cytes), red cells (e.g., erythrocytes) and platelets. 
In one embodiment, the present invention provides a 
method of employing as the DNA sequence a gene capable of 
encoding an amyloid peptide inactivating enzyme or a bio-
logically active derivative or fragment thereof, and employ-
ing as a vector any DNA vector known to one of ordinary skill 
in the art capable of stable maintenance within the targeted 
cell or tissue upon delivery, regardless of the method of deliv-
ery utilized. The method of this invention provides introduc-
ing at least one gene encoding an amyloid peptide inactivat-
ing enzyme into at least one cell of a target tissue for treating 
the mammalian host. Preferably the target tissue is bone mar-
row, and preferably the target cell is a hematopoietic stem 
cell, however, any progenitor cell may be targeted for delivery 
into liver, lung, kidney, muscle or other tissues in contact with 
blood. The method of this invention further provides trans-
plantation of infected target cells into a mammalian host for 
expression of the amyloid peptide inactivating enzyme on cell 
surfaces. Preferably the amyloid peptide inactivating enzyme 
is expressed on the surface of, or secreted by, blood cells such 
as, platelets, red blood cells and white blood cells, or a com-
bination of any of the foregoing. Most preferably, the amyloid 
peptide inactivating enzyme is expressed on red blood cells 
(e.g., erythoroids, erythrocytes). 
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The amyloid peptide inactivating enzyme of the present 
invention is preferably a peptidase or a biologically active 
derivative or fragment thereof. The peptidase, including some 
biologically active variants thereof may be insulysin (also 
known as insulin degrading enzyme or IDE) [human IDE 
GenebankAccession # NM004969]; neprilysin (also known 
to as endopeptidase 24.11, NEP, or CALLA) [human NEP 
Genebank Accession #s NM000902, NM007287, 
NM007289, NM007288]; neprilysin 2 (also known as 
10 secreted endopeptidase, secNEP, or membrane metallo-en-
dopeptidase-like 2) [human NEP2 Genebank Accession # 
NM033467]; endopeptidase 24.15 (also known as thimet oli-
gopeptidase 1) [human endopeptidase 24.15 Genebank 
Accession# NM003249]; endopeptidase 24.16 (also known 
15 as neurolysin) [human endopeptidase 24.16 Genebank 
Accession# NM020726]; endothelin converting enzyme [hu-
man endothelin converting enzyme 1 GenebankAccession # 
NM001397; human endothelin converting enzyme 2 
Gene bank Accession# NM014693]; angiotensin converting 
20 enzyme (also known as dipeptidase A) [human angiotensin 
converting enzyme Genebank Accession #s NM 000789, 
NM152831, NM152830]; plasmin [human plasmin derived 
from human plasminogen Genebank Accession #000301]; 
MMP-9 (also known as gelatinase B) [human MMP-9 
25 Genebank Accession# NM 004994], or similar peptidases. 
Preferably, the peptidase is neprilysin. 
This invention also includes other biologically active 
derivatives or fragments (i.e., variants) ofpeptidases that are 
substantially identical polynucleotides that hybridize to the 
30 complement of a nucleic acid sequence encoding a peptidase 
under stringent hybridization conditions for the isolation of 
nucleic acids that encode peptidases that modulate and/or 
bind to an amyloid peptide, thereby inactivating the amyloid 
peptide. Highly stringent conditions involve hybridizing at 
35 68° C. in 5xSSC/5xDenhart's solution/1.0% SDS, and wash-
ing in 0.2xSSC/0.1% SDS at room temperature. Moderately 
stringent conditions include washing in 3xSSC at 42° C. The 
parameters of salt concentration and temperature can be var-
ied to achieve optimal level of identity between the primer 
40 and the target nucleic acid. Additional guidance regarding 
such conditions is readily available in the art, for example, 
Sambrook and Russel, Molecular Cloning, a laboratory 
manual, (3rd ed.), Cold Spring Harbor Laboratory Press, New 
York, (2001) and F. M. Ausubel eta! eds., Current Protocols 
45 in Molecular Biology, John Wiley and Sons (1994). 
The direct delivery of the DNA vector molecule to the 
target cell or tissue may be a viral or plasmid DNA vector 
molecule. This method includes employing the biologic 
means of utilizing a virus to deliver the DNA vector molecule 
50 to the target tissue. Preferably the virus is a pseudovirus, the 
genome having been altered such that the pseudovirus is 
capable only of delivery and stable maintenance within the 
target cell, but not retaining an ability to replicate within the 
target cell or tissue. Most preferably, the virus is attenuated, 
55 the strain having been selected for diminished virulence so as 
to not spread disease. 
The viral genome may be further manipulated by recom-
binant DNA techniques such that the viral genome acts as a 
DNA vector molecule, which contains the heterologous gene 
60 of interest to be expressed within the target cell or tissue. In a 
preferred embodiment, the DNA vector molecule comprises 
the gene of interest, which may be operatively linked to a 
promoter, transcription enhancer and/or translation enhancer 
to either produce high-level expression or cell specific 
65 expression or both. Promoters, transcription and translation 
enhancers for high-level and/or cell specific expression are 
known to one of ordinary skill in the art. Preferably, the 
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promoter is a white blood cell specific promoter. More pref-
erably, the promoter is a red blood cell specific promoter. 
Most preferably, the promoter is ankyrin-1. Preferred enhanc-
ers include the GATA-1 and HS-40 used in tandem together 
with the ank:yrin-1 promoter. 
12 
Non-limiting examples of preferred viral vectors include 
adenovirus vector, adena-associated virus (AAV) vector, len-
tivirus, murine leukemia virus or herpes-simplex virus (HSV) 
vector, or other viral vectors currently in development, and 
preferably, replication deficient variants thereof. Preferably, 10 
the DNA viral vector is a lentivirus vector. 
may be expanded to include eight to ten males and eight to ten 
females at each MOL Transfer of the CD45 .1 antigen from the 
donor mouse to recipient mice that contain the CD45.2 vari-
ant of this antigen was measured. Both the CD45.1 and 
CD45.2 variants are detected in blood by flow cytometry 
using fluorescein isothiocyanate (FITC) conjugated antibod-
ies and Phycoerythrin (PE) conjugated antibody from Pharm-
ingen. 
Expression ofNeprilysin on Hematopoietic Cells. 
Blood is collected by retro orbital bleeding into heparin-
ized tubes, and diluted with PBS and dextran, the latter to 
0.7% final concentration. The red blood cells and/or white Non-limiting examples of preferred plasmid vectors include pcDNA, pCMV or any other mammalian cells 
expression plasmids containing the CMV promoter or other 
promoters. 
Transplantation preferably occurs via injection of the 
transduced target cells into a mammalian host. The trans-
duced target cells may be directly injected into the bone 
marrow tissue of the mammalian host. Direct intra-bone mar-
row injection of bone marrow stem cells has been described 
by Kushida T, Inaba M, Hisha H et a!. Intra-bone marrow 
injection of allogeneic bone marrow cells: a powerful new 
strategy for treatment of intractable autoimmune diseases in 
MRL/lpr mice. Blood 2001; 97:3292-3299). Preferably trans-
plantation is directed by intravenous injection of the trans-
duced target cells into the blood of the mammalian host. The 
cells may enter bone and serves as a source of bone marrow 
stem cells. Such and other techniques for transplantation of 
the transduced target cells are known to one of ordinary skill 
in the art and are incorporated herein. 
In a preferred embodiment, a lentivirus-neprilysin (lentivi-
rus-NEP) construct is used to transduce hematopoietic stem 
cells derived from bone marrow, which transduced hemato-
poietic stem cells are then transplanted into a mammalian 
host. Transplantation occurs by intravenous injection of the 
infected stem cells into the circulatory system of the mam-
malian host. The transplanted neprilysin expressing stem 
cells continuously express neprilysin on hematopoietic cells, 
e.g., white and red blood cells. The expressed neprilysin 
degrades peripheral A~ and results in a lowering of brain A~ 
through a "sink effect". Without intending to be limited by 
theory, it is hypothesized that reduction of peripheral A~ 
causes an imbalance in A~ levels in the periphery and the 
CNS, resulting in A~ from the brain to be drawn out of the 
CNS into the periphery as A~ levels in the periphery decrease. 
Transduction of Hematopoietic Stem Cells. 
Transduction of hematopoietic stem cells is performed 
using bone marrow cells derived from a C57BL/6 donor 
mouse carrying the leukocyte common antigen variant 
CD45.1. These cells are transduced with a lentivirus-NEP. 
The transduced bone marrow cells are subsequently trans-
planted into a sublethally irradiated (600 rads for 3 min.) 
C57BL/6 recipient mouse that expresses the lenkocyte com-
mon antigen variant CD45.2. Optimization of neprilysin 
expression is carried out by varying the multiplicity of infec-
tion (MOl) from 10 to 100 to 1000. Twenty four (24) mice 
may be used for these studies, 8 at each MOL For each 8 at 
each MOl, the groups can be further subdivided into 4 males 
and 4 females to look for trends in expression based on sex 
differences, as sex differences in the extent of amyloid depo-
sition have been reported in hAPP transgenic mice. (Callahan 
M J, et a!. (2001) Augmented senile plaque load in aged 
female beta-amyloid precursor protein-transgenic mice. Am 
J Pathol. 158: 1173-7; Lee JY, eta!. (2002)). Contribution by 
synaptic zinc to the gender-disparate plaque formation in 
human Swedish mutant hAPP transgenic mice. Proc Nat! 
Acad Sci USA. 99:7705-10). If a trend is observed the study 
blood cells are collected after incubation at 3 7° C. and resus-
15 pended in PBS for flow cytometry analysis for neprilysin 
using an FITC conjugated monoclonal antibody CLB-
CALLA/1,4F9 from Research Diagnostics Inc. and for 
neprilysin activity measurements as noted below. The super-
natant is used to measure the percent ofCD45 .1 positive cells 
20 by flow cytometry. We have previously shown that dilution of 
purified neprilysin into heparinized tubes does not affect its 
enzymatic activity (data not included) thus validating the 
ability to collect blood from animals and measure neprilysin 
activity without complications and artifacts from the collec-
25 tion method. It may be advantageous to lyse the red blood 
cells and isolate plasma membranes by centrifugation at 100, 
OOOxg for 1 hr. The membrane fraction contains the nepril-
ysin activity, which was confirmed in initial preliminary 
30 
experiments. 
Measuring Neprilysin Activity. 
Neprilysin activity is measured with glutaryl-Ala-Ala-
Phe-X where X=AMC (aminomethylcoumarin), MNA 
(methoxynaphthylamine) or -pNA (para-nitroaniline) as a 
specific synthetic substrate (Li C, Hersh LB. (1995) Nepril-
35 ysin: assay methods, purification, and characterization. 
Methods Enzymol. 248:253-63.). Neprilysin cleaves glu-
taryl-Ala-Ala-Phe-X releasing glutaryl-Ala-Ala and Phe-X. 
The reaction is stopped and the Phe-X is secondarily cleaved 
to free Phe and either the highly fluorescent 
40 AMC=aminomethylcoumarin or methoxynaphthylamine 
groups or the visible para-nitroaniline by an added aminopep-
tidase, aminopeptidase M. The released aminomethylcou-
marin or methoxynaphthylamine is quantitated fluorometri-
cally while the released para-nitroaniline is quantitated 
45 spectrophotometrically. 
A modified one-step continuous assay using a recombinant 
aminopeptidase produced in the Hersh laboratory may be 
used in place of the two-step assay (Li and Hersh, 1995). The 
recombinant aminopeptidase is added directly to the assay in 
50 excess such that the reaction is monitored continuously. 
Thompson, M. W. and Hersh L. B., Analysis of conserved 
residues of the human puromycin-sensitive aminopeptidase. 
Peptides. 2003 September; 24(9):1359-65; Ma Z, eta!. Pro-
teolytic cleavage of the puromycin-sensitive aminopeptidase 
55 generates a substrate binding domain. Arch Biochem Bio-
phys. 2003 Jul. 1; 415(1):80-6; Thompson M W, Govin-
daswami M, Hersh LB. Mutation of active site residues of the 
puromycin-sensitive aminopeptidase: conversion of the 
enzyme into a catalytically inactive binding protein. Arch 
60 Biochem Biophys. 2003 May 15; 413(2):236-42. The one-
step assay has been further modified for use in a 96 or 384 well 
fluorescence plate reader. This modified assay is about 10 
times more sensitive than the discontinuous assay, it permits 
linear initial rates to be measured, and it accommodates mul-
65 tiple samples to be assayed at the same time. The neprilysin 
inhibitors thiorphan and phosphoramidon are used to deter-
mine the specificity of the reaction. 
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Once an optimal multiplicity of infection (MOl) is estab-
lished, the time course for expression of neprilysin from one 
to twelve months is determined by both fluorescence acti-
vated cell sorting (F ACS) and determination of enzyme activ-
ity. Neprilysinlevels at 1, 2, 4, 6, 9, and 12months from blood 
obtained through orbital bleeding is measured. This follows 
since it has been shown that the peripheral administration of 
A~ binding agents (gelsolin or ganglioside GM1) lowered A~ 
levels within a month (Matsuoka eta!., 2003). 
Non-Tg C57BL/6 mice for optimizing expression of 10 
neprilysin on bone marrow stem cells may be used and to 
minimize the cost involved in producing or purchasing hAPP 
14 
from these mice are collected and used to measure total brain 
A~, A~ 1_40 and A~ 1_42 levels. For measuring A~ levels, the A~ 
peptides are extracted with formic acid according to the pro-
cedure of Refolo L M, et a!. Hypercholesterolemia acceler-
ates the Alzheimer's amyloid pathology in a transgenic 
mouse model. Neurobiol. Dis. 7:321-31 (2000), or with 
guanidine (Masliah E, et a!. beta-amyloid peptides enhance 
alpha-synuclein accumulation and neuronal deficits in a 
transgenic mouse model linking Alzheimer's disease and Par-
kinson's disease. Proc Nat! Acad Sci USA. 2001 Oct. 9; 
98(21):12245-50) and then determined by sandwich ELISA 
using kits available from Biosource International. To deter-
mine the fraction of A~ present as oligomers, the sample is Tg mice. C57BL/6NCr mice are obtained from the National Cancer institute-Frederick, Animal Production Program, Fre-
derick, Md. 
Transplantation and Analyzing A~ Levels. 
Once the expression of neprilysin has been optimized in 
C57BL/6 mice the optimal parameters are used to express 
neprilysin in the 120 or other hAPP transgenic mouse lines, 
15 subjected to PAGE using Tricine gels (commercially avail-
able from Invitrogen) and immunostained with monoclonal 
antibody 6E10 (Signet Pathology Systems, Inc.) or our own 
polyclonal antisera made to A~ residues 21 to 30. 
i.e. the 3x-Tg mouse ofOddo eta!. (Triple-transgenic model 20 
of Alzheimer's disease with plaques and tangles: intracellu-
lar Abeta and synaptic dysfunction. Neuron. 39:409-421 
(2003) ). Bone marrow transplantation is performed into mice 
two months of age and measure A~ levels every month out to 
eighteen months. Plasma is obtained either through orbital 25 
bleeding or tail bleeding into heparinized tubes without sac-
rificing the animals, or if necessary from trunk blood after 
sacrifice. The method of obtaining blood and therefore the 
number of animals required depends on the A~ levels and the 
sensitivity of our assay. Plasma is obtained by centrifugation 30 
at 1,000xg for 10 min and used for A~ determination. The 
plasma A~ levels in 120 or other hAPP Tg mice receiving 
bone marrow cells transduced with wild type neprilysin is 
compared to 120 or other hAPP mice receiving lentivirus 
expressing an E585V neprilysin mutant, which is an inactive 35 
form of the enzyme. 
The plasma A~ levels are determined by sandwich ELISA. 
Commercial ELISA kits from Biosource International or 
ELISA plates produced in the laboratory from commercially 
available antisera can be used. These are mouse monoclonal 40 
antibodies 6E1 0 and 4G8 to human amyloid beta protein, or a 
rabbit polyclonal antibody to specific to A~ 40 or specific to 
A~ 42 respectively, obtained from Signet, (Dedham, Mass.) 
to measure total A~, as well as measuringA~40 andA~42 . To 
determine the fraction of A~ present as oligomers, the plasma 45 
sample is subjected to PAGE using Tricine gels commercially 
available from Invitrogen and immunostained with mono-
clonal antibody 6E1 0 (Signet Pathology Systems, Inc.) or our 
own polyclonal antisera made to A~ residues 21 to 30. 
Analyzing Expression of Neprilysin on Hematopoietic 50 
Cells on Brain A~ Levels and Amyloid Deposition in the 
Brain ofhAPP Transgenic Mice 
Having determined the time course and to what extent 
plasma A~ levels can be decreased by expression of nepril-
ysin on hematopoietic cells, the effect of this peripheral 55 
neprilysin expression on brain A~ levels is tested. Forty eight 
( 48) two-month old hAPP transgenic mice (i.e., the 120 
mouse or the "triple transgenic" mouse of Oddo S et a!. 
triple-transgenic model of Alzheimer's disease with plaques 
and tangles: intracellular Abeta and synaptic dysfunction. 60 
Neuron. 39:409-421 (2003)), half undergoing bone marrow 
transplantation with stem cells expressing neprilysin and the 
other half undergoing bone marrow transplantation with stem 
cells expressing the inactive E585V mutant neprilysin are 
used. Six mice in each group (active versus inactive nepril- 65 
ysin) are sacrificed at 3 month intervals for up to eighteen 
months following maximal neprilysin expression. The brains 
Another group of thirty experimental and thirty control 
mice are treated in a similar manner as above except that A~ 
deposition in these animals is measured. In both the 120 hAPP 
and the 3x-Tg mouse A~ amyloid deposition is observed at 
about 6 to 9 months of age and increases thereafter. Therefore 
bone marrow transplantation is performed at about 2-3 
months of age and the mice are euthanized at 6, 9, 12, 15 and 
18 months of age in groups of 6. The mice are perfused 
transcardially with 4% paraformaldehyde, the brains 
removed and fixed overnight at 4 o C. The fixed brains are 
rinsed in PBS, dehydrated, and then embedded in paraffin and 
sectioned. Histological staining with hematoxylin-eosin, 
cresyl-violet or silver impregnation as described by Bruce et 
a!. (1996) is performed. Bruce, A. 1. et a!. (1996) Altered 
neuronal and microglial responses to excitotoxic and 
ischemic brain injury in mice lacking TNF receptors. Nat. 
Med. 2: 788-794. Amyloid deposits are detected in cryostat 
sections by incubation overnight at 4 o C. with biotinylated 
mouse monoclonal antibodies 4G8) from (Signet, Dedham, 
Mass.), The Elite kit from Vector Laboratories is used to 
detect binding of the primary antibody. Sections are counter-
stained with hematoxylin/eosin and examined with a Nikon 
light microscope. A minimum often sections per mouse are 
examined. The number of plaques are counted and the size of 
the plaques in the hippocampus are measured. 
Analyzing Effect of Expression ofNeprilysin on Hemato-
poietic Cells and the Number of Amyloid Plaques in Older 
hAPP Tg Mice. 
To demonstrate the hypothesis that lowering of brain A~ 
levels through peripheral expression of neprilysin in the 
plasma of older hAPP Tg mice leads to a decrease in the 
number of preformed amyloid deposits, the same basic pro-
tocol as set forth above is used except that the recipient hAPP 
transgenic mice (i.e. 120 mice) are 18-20 months old, a time 
in which amyloid deposits are numerous in this transgenic 
line. Bone marrow stem cells are transduced at the optimal 
viral MOl and then bone marrow transplantation is performed 
into the older 120 mice as described herein. Plasma A~ levels 
through analysis ofblood obtained through orbital or tail vein 
bleeding. Once the plasma A~ levels have been decreased to 
a steady-state level, the animals are sacrificed at various times 
(1 to 3 months initially) to determine if clearance of plasma 
A~ has reversed amyloid plaque deposition in the brain. In 
our studies with direct expression of neprilysin in the brains 
of older mice (Marr et a!, 2002), a decrease in the number of 
amyloid plaques was observed within a month. Ten (10) mice 
expressing wild type neprilysin on red blood cells are com-
pared to ten (10) mice expressing the inactive mutant nepril-
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ysin on red blood cells at one month, three months, six 
months, and then at 6 month intervals until 2 years of age if 
feasible. 
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Transcardial perfusion with 4% paraformaldehyde is used 
after which the brains are removed and fixed. The fixed brains 
are rinsed in PBS, dehydrated, and then embedded in paraffin. 
Histological staining is performed on the paraffin embedded 
sections, with amyloid deposits detected with biotinylated 
mouse monoclonal antibodies 3D6 and 1 ODS as noted above. 
Counterstained sections are quantitated with a Nikon light 
microscope. At least ten sections per mouse are used where 
the number, size, and appearance of plaques in the hippoc-
ampus determined. To ensure that the results obtained are not 
unique to the particular HAPP mouse line, (i.e. the J20 15 
mouse) hAPPswE_presenilin-1 mice commercially available 
from Jackson labs or the triple transgenic mouse line will be 
used as controls. 
The present invention discloses ex vivo and in vivo tech-
niques for coupling amyloid peptide inactivating enzyme 
with hematopoietic cells. Generally, the ex vivo techniques 
involve taking a sample of hematopoietic cells, in vitro cou-
pling of one or more amyloid peptide inactivating enzyme to 
one or more hematopoietic cell, followed by transplantation 
of the sample having amyloid peptide inactivating enzyme-
bound hematopoietic cells to the mmalian host, so as to 
effect increased presence and activity of peripheral amyloid 
10 peptide inactivating enzyme. It will be understood by the 
artisan of ordinary skill that the preferred source of hemato-
poietic cells for treating a human patient is the patient's own 
hematopoietic cells, such as red and white blood cells. 
There are many techniques known by the skilled artisan for 
coupling one or more molecule or compound to another, 
which may be used to practice the present invention. In one 
preferred embodiment, coupling may be achieved by bioti-
nylating one or more amyloid peptide inactivating enzyme In Vivo Delivery of Amyloid Peptide Inactivating Enzyme. 
In another embodiment the present invention involves 
direct in vivo delivery of an amyloid peptide inhibiting 
enzyme gene to the bone marrow tissue of a mmalian host 
through use of either an adenovirus vector, adena-associated 
virus (AAV) vector, lentivirus, or herpes-simplex virus 
(HSV) vector, murine leukemia virus (MuLV) or other viral 
vectors currently in development. In this embodiment, a DNA 
sequence of interest encoding a functional amyloid peptide 
inhibiting enzyme or enzyme fragment is subcloned into the 
respective viral vector. The amyloid peptide inhibiting 
enzyme gene containing viral vector is then grown to 
adequate titer and introduced into the bone marrow, prefer-
ably by injection into blood. In an exemplary procedure, the 
region from the inguen to the knee joint is shaved, and a 5-mm 
incision is made on the thigh. The knee is flexed to about a 90° 
angle, and the proximal side of the tibia is drawn to the 
anterior. A 26-gauge needle is inserted into the joint surface of 
the tibia through the patellar tendon and then inserted into the 
BM cavity. Using a microsyringe (50 f.tl; Hamilton Co.; Reno, 
Nev.). Bone marrow cells are injected from the bone holes 
into the bone marrow cavities of both tibiae. 
Direct bone marrow tissue injection of a DNA molecule 
containing the gene of interest results in transfection of the 
recipient bone marrow tissue cells and hence bypasses the 
requirement of removal, in vitro culturing, transfection, 
selection, as well as transplanting the DNA vector containing 
hematopoietic stem cells to promote stable expression of the 
heterologous gene of interest. 
In another embodiment, and as an additional alternative to 
the in vitro manipulation of hematopoietic stem cells, the 
gene encoding the product of interest is introduced into the 
area of bone marrow tissue as naked DNA. The naked DNA 
enters the bone marrow tissue cells, preferably hematopoietic 
stem cells, resulting in an in vivo gene expression of the 
amyloid peptide inhibiting enzyme on hematopoietic cells. 
Coupling Amyloid Peptide Inactivating Enzyme to 
Hematopoietic Cells. 
In another aspect the present invention provides methods 
of reducing amyloid peptide in the brain comprising inacti-
vating peripheral amyloid peptide by coupling amyloid pep-
tide inactivating enzymes to hematopoietic cells. Without 
intending to be bound by theory, by coupling one or more 
amyloid peptide inactivating enzyme to one or more hemato-
poietic cell the amyloid peptide inactivating enzyme is not 
degraded in vivo so rapidly. The longer the amyloid peptide 
inactivating enzyme is in circulation increases the opportu-
nity of the amyloid peptide inactivating enzyme coming into 
contact with peripheral A~ and inactivating the peripheral A~. 
20 and one or more hematopoietic cell of a mmalian host, and 
linking the biotin of one or more of each the enzyme and the 
hematopoietic cell using streptavidin and/or avidin, in accor-
dance with the protocol set forth and incorporated in its 
entirety by reference herein (Dominici S, et a!. Red blood 
25 cell-mediated delivery of recombinant HIV-1 Tat protein in 
mice induces anti-Tat neutralizing antibodies and CTL. Vac-
cine. May 16; 21(17-18):2073-81 (2003)). Other cross-link-
ing reagents may also be used to link the two molecules to 
effect coupling of enzyme and hematopoietic cells. Non-
30 limiting examples of such other cross-linking reagents 
include glutaraldehyde, (Perez M T et a!. In vivo studies on 
mouse erythrocytes linked to transferrin. IUBMB Life. 2002 
September; 54(3): 115-21 ). 
In another preferred embodiment, coupling may be 
35 achieved by modifYing one or more amyloid peptide inacti-
vating enzyme such that the modified enzyme binds to one or 
more hematopoietic cell. Preferably, one or more amyloid 
peptide inactivating enzyme is modified to contain a C-ter-
minal human red blood cell binding peptide sequence as 
40 described in, and incorporated in its entirety by reference 
herein, Garcia J E, et a!. Peptides from the Plasmodium fal-
ciparum STEVOR putative protein bind with high affinity to 
normal human red blood cells. Peptides. 2005 July; 26(7): 
1133-43; Lopez R, eta!. Plasmodiumfalciparum: red blood 
45 cell binding studies of peptides derived from histidine-rich 
KAHRP-I, HRP-II and HRP-III proteins. Acta Trap. 2000 
May 31; 75(3):349-59. It is also preferable to modify one or 
more amyloid peptide inactivating enzyme such that it is 
coupled or bound to an antibody to a hematopoietic cell in 
50 accordance with the methods described in, and incorporated 
in its entirety by reference herein, Spitzer D, et a!., ScFv-
mediated in vivo targeting of DAF to erythrocytes inhibits 
lysis by complement. Mol Immunol. 2004 February; 40(13): 
911-9. An antibody to a hematopoietic cell may be an anti-
55 body to a red blood cell or a white blood cell, or a platelet or 
capable of binding all three. Due to such modifications, the 
modified enzymes are able to couple to one or more hemato-
poietic cell. 
In another preferred embodiment, coupling may be 
60 achieved by modifYing one or more amyloid peptide inacti-
vating enzyme such that the modified enzyme contains a 
glycoinositol phospholipid (GPI) that permits direct insertion 
of the protein into the membrane of one or more hematopoi-
etic cells. Preferably, one or more amyloid peptide inactivat-
65 ing enzyme is modified to contain a GPI anchor as described 
in and incorporated herein by reference Howell S, Lanctot C, 
Boileau G, and Crine P, Expression of an enzymically active 
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glycosylphosphatidylinositol-anchored form of neutral 
endopeptidase (EC 3.4.24.11) in Cos-1 cells, Biochem. J. 
(1994) 299:171-176. 
In vivo techniques for coupling one or more amyloid pep-
tide inactivating enzyme to one or more hematopoietic cell of 
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compound. The amount of the drug in a formulation can vary 
within the full range employed by those skilled in the art, e.g., 
fromaboutO.Ol weight percent (wt %) to about 99.99 wt% of 
the drug based on the total formulation and about 0.01 wt% 
to 99.99 wt% excipient. 
a mammal involve, modifYing in vitro one or more amyloid 
peptide inactivating enzyme such that it will bind to one or 
more hematopoietic cell and introducing the modified amy-
loid peptide inactivating enzyme into a mammalian host, 
preferably by injection into the blood or bone marrow. Amy- 10 
laid peptide inactivating enzymes are modified as described 
above or in any such other marmer so that the modified 
enzyme is capable of coupling with or to one or more hemato-
poietic cell. 
The preferred mode of administration, for the conditions 
mentioned above, is oral administration using a convenient 
daily dosage regimen, which can be adjusted according to the 
degree of the complaint. For said oral administration, a phar-
maceutically acceptable, non-toxic composition is formed by 
the incorporation of the selected pharmacological compound 
in any of the currently used excipients, such as, for example, 
pharmaceutical grades of marmitol, lactose, starch, magne-
sium stearate, sodium saccharine, talc, cellulose, glucose, 
gelatin, sucrose, magnesium carbonate, and the like. Such 
compositions take the form of solutions, suspensions, tablets, 
Pharmacological Agents to Induce Synthesis or Activity of 15 
Amyloid Peptide Inactivating Enzyme. 
In another aspect the present invention provides the use of 
pharmacological agents to induce synthesis of the endog-
enous gene encoding peripheral amyloid peptide inhibiting 
enzyme. Such a pharmacological substance may be a com- 20 
pound that "up regulates" or enhances the expression of 
peripheral amyloid peptide inhibiting enzyme. The pharma-
cological agent may bind to the regulatory region of the gene 
encoding the peripheral enzyme and thus activate its gene 
expression. Thus, the compound may be a transcriptional 25 
activator of the gene encoding the enzyme. Or, the compound 
may have a regulatory effect post transcriptionally in, for 
example, stabilizing the amyloid peptide inhibiting enzyme 
structure. 
pills, capsules, powders, sustained release formulations and 
the like. Such compositions may contain between 0.01 wt% 
and 99.99 wt% of the active compound according to this 
invention. 
Preferably the compositions have the form of a sugar 
coated pill or tablet and thus contain, along with the active 
ingredient, a diluent such as lactose, sucrose, dicalcium phos-
phate, and the like; a disintegrant such as starch or derivatives 
thereof; a lubricant such as magnesium stearate and the like; 
and a binder such as starch, polyvinylpyriolidone, acacia 
gum, gelatin, cellulose and derivatives thereof, and the like. 
It is understood that by "pharmaceutical composition", it is 
meant that the pharmacological compound is formulated into 
In still another aspect, pharmacological agents can be used 
to increase the activity of the peripheral amyloid peptide 
inhibiting enzyme. Such a pharmacological substance may be 
a compound that enhances the activity of the peripheral amy-
loid peptide inhibiting enzyme. The pharmacological agent 
may modulate the activity of the amyloid peptide inactivating 
enzyme, causing an increase in activity of the peripheral 
amyloid peptide inhibiting enzyme. Amyloid peptide inacti-
vating enzyme enhancing substances may be bound to either 
one or both of amyloid peptide inactivating enzymes modi-
fied to couple with hematopoietic cells and hematopoietic 
cells for enhanced peripheral amyloid peptide inactivating 
activity. 
The pharmacological agent may be placed in pharmaceu-
tically acceptable excipient or carrier and administered to a 
person or individual in need thereof. Depending on the spe-
cific clinical status of the disease, administration can be made 
via any accepted systemic delivery system, for example, via 
oral route or parenteral route such as intravenous, intramus-
cular, subcutaneous or percutaneous route, or vaginal, ocular 
or nasal route, in solid, semi-solid or liquid dosage forms, 
such as for example, tablets, suppositories, pills, capsules, 
powders, solutions, suspensions, cream, gel, implant, patch, 
pessary, aerosols, collyrium, emulsions or the like, preferably 
in unit dosage forms suitable for easy administration of fixed 
dosages. The pharmaceutical compositions include a conven-
tional carrier or vehicle and the pharmacological compound 
and, in addition, may include other medicinal agents, phar-
maceutical agents, carriers, adjuvants, and so on. 
If desired, the pharmaceutical composition to be adminis-
tered may also contain minor amounts of non-toxic auxiliary 
substances such as wetting or emulsifYing agents, pH buffer-
ing agents and the like, such as, by non-limiting example, 
sodium acetate, sorbitan monolaurate, triethanolamine ole-
ate, and so on. 
The compounds of this invention are generally adminis-
tered as a pharmaceutical composition comprising a pharma-
ceutical vehicle in combination with the pharmacological 
30 a substance that is to be administered purposefully for modu-
lating amyloid peptide inactivating enzymes to inactivate 
peripheral amyloid protein. The mode of action is believed to 
be by hydrolytic cleavage of the amyloid peptide by the 
amyloid inactivating enzyme U.S. Published PatentApplica-
35 tion No. 2003/0165481 published on Sep. 3, 2004. However, 
it is understood that the pharmacological compound per se 
will not have a toxic effect, and by "pharmaceutical compo-
sition", it excludes those compositions that are used to admin-
ister to individuals as test compounds for a purpose other than 
40 as an inducer of inactivation of the amyloid protein. 
Treating and/or Preventing Alzheimer's Disease 
It is another aspect of the present invention to treat and/or 
prevent Alzheimer's Disease. In one embodiment, the method 
comprises administering to a patient in need thereof a thera-
45 peutically effective amount of stem cells transduced with a 
DNA vector encoding an amyloid peptide inactivation 
enzyme as described herein. Preferably the stem cells are 
hematopoietic stem cells including but not limited to red 
blood cells, white blood cells, and platelets. Preferably the 
50 DNA vector is a viral vector, and most preferably a lentivirus 
vector or an adena associated virus vector. It is also preferable 
that the amyloid peptide inactivating enzyme is a peptidase, 
and most preferably, the peptidase is neprilysin or a biologi-
cally active derivative or fragment thereof. In another pre-
55 ferred embodiment, the method comprises administering (ex 
vivo or in vivo) to the hematopoietic stem cells of a patient in 
need thereof a therapeutically effective amount of a recom-
binant viral vector or plasmid vector comprising a nucleotide 
sequence encoding an amyloid peptide inactivating enzyme 
60 operatively linked to a promoter such that it is expressed on 
the surface of or secreted from hematopoietic cells. 
In another embodiment, the present invention provides a 
method for treating and/or preventing Alzheimer's disease by 
administering to the hematopoietic cells of a patient in need 
65 thereof a thereapeutically effective amount of amyloid pep-
tide inactivating enzyme. Preferably the enzyme is adminis-
tered by coupling amyloid peptide inactivating enzyme to 
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hematopoietic cells as described herein. Coupling may be 
performed ex vivo and then the enzyme-coupled hematopoi-
etic cells are transplanted in to a patient, or it may occur in 
vivo via modified amyloid peptide inactivating enzymes. 
Preferably, coupling is performed ex vivo via biotinylation of 
amyloid peptide inactivating enzyme and hematopoietic cells 
and using streptavidin and/or avidin to link one or more 
biotiny Ia ted enzyme to one or more hematopoieteic cell. Cou-
piing is preferably performed in vivo by modifying amyloid 
peptide inactivating enzyme and introducing the modified 10 
enzyme into a patient. Preferably, amyloid peptide inactivat-
ing enzyme is modified to contain either a C-terminal human 
red blood cell binding peptide sequence, or a glycoinositol 
phospholipids (GPI) anchor. It is also preferable to bind an 
antibody to a hematopoietic cell to an amyloid peptide inac- 15 
tivating enzyme to produce a chimeric protein in which the 
antibody combining region is directed against a hematopoi-
etic cell surface protein. Preferably the modified enzyme is 
introduced by injection into the blood of a patient. 
20 
globin gene regulatory elements after lentiviral vector-medi-
ated gene transfer into primitive human and murine hemato-
poietic cells. Hum Gene Ther. 13:2007-2016, and Moreau-
Gaudry F, et a!. (2001) High-level erythroid-specific gene 
expression in primary human and murine hematopoietic cells 
with self-inactivating lentiviral vectors. Blood 98:2664-
2672. These are self-inactivating lentiviral vectors that use an 
erythroid specific enhancer in combination with the wood-
chuck hepatitis virus post regulatory element and produce 
erythroid specific expression in both murine and human cell 
lines. In a preferred embodiment, the lentivirus constructs 
contain ank:yrin-1 promoter in combination with two enhanc-
ers in tandem (the GATA-1 and HS-40). FIG. 8 (A-B) illus-
trates exemplary lentiviral constructs for the expression of 
NEP on red blood cells. 
EXAMPLE3 
Neprilysin in Genetic Therapy Approach to Treat 
Alzheimer's Disease (AD) 
To evaluate the use of neprilysin as a potential candidate for 
a gene therapeutic approach for treating AD, the following 
lentivirus constructs were tested, comprising: (1) the nepril-
ysin gene (NEP), (2) an inactive point mutant of neprilysin 
(NEPx), (3) a secreted form of neprilysin (SecNEP) that 
produces the extracellular domain, and ( 4) green fluorescent 
protein (GFP), each driven by the cytomegalovirus (CMV) 
promoter. These constructs were initially tested in a Chinese 
In another embodiment, there is a method for treating 20 
and/or preventing Alzheimer's disease by administering to 
the blood of a patient a therapeutically effective amount of an 
amyloid peptide inactivating enzyme-containing liposome or 
other delivery agent. Preferably, the amyloid peptide inacti-
vating enzyme-containing liposomes introduce the enzyme 25 
into hematopoietic cells of the patient. The amyloid peptide 
inactivating enzyme-containing liposome may be delivered 
ex-vivo into the hematopoietic cells of a patient and then 
transplanted into a patient or delivered in vivo into the 
hematopoietic cells of a patient. 30 hamster ovary (CHO) cell line, 7PA2, (obtained from Dr. 
EXAMPLE 1 
Deunis Selkoe) that is stably transfected with hAPP and that 
secretes relatively large amounts of A~ into the media. As 
shown in FIG. 2, transduction of CHO 7PA2 cells with len-
tivirus expressing neprilysin or the secreted form of nepril-Lentivirus Constructs for Expression in 
Hematopoietic Cells 35 ysin produces a large decrease in the concentration of A~ 1_42 
and A~ 1-40 in the media. In contrast, the inactive form of 
neprilysin produced no significant effect. We further found 
that transduction of the CHO 7PA2 cell line at a low multi-
Lentivirus constructs for expression in hematopoietic cells 
were generated as described by Dull T, et a!. A third-genera-
tion lentivirus vector with a conditional packaging system. J 
Viral. 1998 November; 72(11):8463-71.). Vector plasmids 40 
were constructed for the production of third generation len-
tiviral vectors. All vectors were designed to be self-inactivat-
ing and used the woodchuck hepatitis virus post-transcrip-
tional regulatory element (WPRE) 3' to the transgene. The 
human cytomegalovirus (CMV) promoter was used to drive 45 
expression of the transgenes. The HIV-1 central poly-purine 
track were also located 5' to the promoter. Lentiviral vectors 
were produced using a four plasmid transfection system, as 
described by Dull eta!. 1998. Briefly, 293T cells were trans-
fected with vector and packaging plasmids, the supernatants 50 
are collected, and vectors are concentrated by centrifugation. 
The lentiviral vector titers were estimated by measuring the 
amount ofHIV p24 gag antigen with an ELISA kit (Zeptom-
etrix Co., Buffalo, N.Y.). FIG. 1 illustrates an exemplary 
lentiviral vector construct used for expression of NEP on 55 
hematopoietic cells. 
EXAMPLE2 
plicity of infection, about 1 multiplicity of infection (MOl), 
produced a similar effect to that shown in FIG. 2 indicating 
that even low level expression of neprilysin is sufficient to 
efficiently degrade extracellular A~. Dr. Selkoe's group has 
recently measured the kinetics of A~ hydrolysis by neprilysin 
using anA~ analog (Leissring MA, eta!. (2003) Kinetics of 
amyloid beta-protein degradation determined by novel fluo-
rescence- and fluorescence polarization-based assays. J. Bioi 
Chern. 278:37314-20) and found a Km of about 10 f.LM. 
EXAMPLE4 
Transduction of Murine Bone Marrow Cells and 
Bone Marrow Transplantation 
Bone marrow was harvested from 6-week-old C57BII 
LY5.1 mice (B/6.SJL-CD45a-Pep3b, Jackson Laboratory, 
Bar Harbor, Me.) (CD45.11) by flushing femurs and tibiae. 
Lineage-negative cells were purified with the Hematopoietic 
Progenitor Enrichment kit from Stemcell Technologies. 
Enriched progenitor cells were prestimulated with Iscove's 
Lentivirus Constructs for Expression in Red Blood 
Cells 
60 modified Dulbecco's medium (IMDM; Gibco, Grand Island, 
N.Y.) supplemented with 10% FCS containing 10 ng/mL of 
each of the following cytokines: miL3, miL6, hF!t3 ligand 
and 50 ng/ml hSCF (R&D, Minneapolis, Miun.) overnight 
and then transduced with lentiviral vectors two times at 
Lentivirus constructs for expression in red blood cells were 
generated in the laboratory of Dr. Punam Malik of UCLA 
according to the methods described in and incorporated in 65 
their entirety by reference herein to Hanawa H, eta!. (2002) 
High-level erythroid lineage-directed gene expression using 
24-hour intervals. On day 3, cells were washed twice with 
phosphate buffered saline (PBS) and 2x105 hematopoietic 
cells/mouse were injected into the tail vein of 8-week-old 
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rec1p1ent male PDAPP mice (transgenic C57BL/6-ly5.2 
(CD45.21) mice that over express mutant human amyloid 
precursor protein eDNA (hAPPV717F) under the control of 
the platelet-derived growth factor promoter), which was sub-
lethally irradiated to allow full engraftment of the trans- 5 
planted hematopoietic stem cells (6 Gy). 
As shown in FIG. 4, transplantation of bone marrow cells 
from a donor mouse expressing the leukocyte common anti-
gen variant CD45 .1 into a sublethally irradiated ( 600 Rads for 
3 min) two month old CD45.2 positive recipient mouse gen- 10 
erates a chimeric animal in which 30 days after transplanta-
tion approximately one third of the circulating hematopoietic 
cells are derived from the donor as shown by the number of 
CD45.1 positive cells. The generation of these chimeric mice 15 
demonstrates the ability to isolate bone marrow stem cells and 
to successfully perform bone marrow transplantation in mice. 
FIG. 4A is a histogram of a recipient mouse's white blood 
cells 30 days after bone marrow transplantation. FITC con-
jugated anti CD45.1 antibody A20 (PharMingen) was used. 20 
Cells in the M1 region are CD45 .1 +donor cells and represent 
about 30% of the total cells. FIG. 4B is a histogram of the 
same recipient mouse's white blood cells as in the left panel, 
but without FITC conjugated anti CD45 .1 antibody. There are 
less than 0.1% cells appearing as CD45.1 positive cells. FIG. 25 
4C is a histogram of a recipient mouse without bone marrow 
transplantation. There are less than 0.1% cells appearing as 
CD45.1 +cells. 
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ent mouse receiving inactive NEP-lentivirus transduced bone 
marrow cells and shows greater than 20% of the white blood 
cells express neprilysin. 
EXAMPLE 6 
ELISA Quantitation of Brain A~ Peptides 
One (1) year after bone marrow transplantation as set forth 
in Example 4, animals were sacrificed and peripheral blood 
and brain were harvested. In blood, red blood cells (RBCs, 
erythrocytes) were analyzed before RBC lysis for white 
blood cell (WBC, lymphocytes) analyses. FACS analysis was 
performed for donor cells (CD45.2), NEP expression in dif-
ferent lineages (T cells, B cells, granulocytes, and RBCs ), and 
DNA analysis to determine proviral copy number. 
Brains were removed immediately after euthanasia of the 
mice by C02 narcosis, frozen in liquid nitrogen, and stored 
frozen until extraction. Brains were homogenized in 5M 
guanidine.HCl in 50 mM Tris.HCI. After incubation for 4 hat 
room temperature, the homogenate was diluted with cold 
BSAT-DPBS buffer (5% BSA, 0.03% Tween-20 in DPBS) 
and centrifuged at 16,000xg for 20 min at 4° C. to remove 
insoluble material. Supernatant fractions were analyzed for 
A~40 andA~42 using isoform-specific ELISA kits (Biosource 
International, Camarillo, Calif.). As set out in FIG. 6, mice 
with bone marrow transplantation of white blood cells 
expressing active NEP showed reduction of A~ levels in the 
brain over mice with bone marrow transplantation of white 
EXAMPLES 
Neprilysin Expression on White Blood Cells 
30 blood cells expressing inactive NEP. Mice with bone marrow 
transplantation of white blood cells expressing active NEP 
showed about a 47.5% reduction inA~ 1-40 levels in the brain. 
Mice with bone marrow transplantation of white blood cells 
As shown in FIG. S, the NEP-lentivirus are used to trans-
duce bone marrow stem cells from a donor mouse as 35 
described in FIG. 4 which are transplanted into a two month 
old recipient mouse producing neprilysin expression on white 
blood cells. About 65% of the white blood cells expressed 
neprilysin prior to transplantation, however since the white 40 
blood cells represent -1% of total blood cells, a relatively 
small amount ofNEP expression is obtained. 
FIG. SA (left) is a histogram of a recipient mouse 30 days 
after bone marrow transplantation. FITC conjugated anti-
NEP antibody CLB-CALLA/1,4F9 (RDI) was used. Cells in 45 
the M2 region are neprilysin positive cells and represent 
about 30% of the total cells. FIG. SA (middle) is a histogram 
of a recipient mouse without bone marrow transplantation. 
There are less than 0.1% cells appearing as neprilysin positive 
cells. FIG. SA (right) is a histogram of a recipient mouse after 50 
bone marrow transplantation without FITC conjugated anti 
CLB-CALLA/1 ,4F9 antibody. There are less than 0.1% cells 
appearing as CD45.1 positive cells. 
FIG. SB is a repeat and extension of the experiment ofFIG. 
SA. The NEP-lentivirus was used to transduce bone marrow 55 
stem cells from a donor mouse, which were transplanted into 
expressing active NEP showed about a 30% reduction in 
A~ 1_42 levels in the brain. 
EXAMPLE 7 
Biotinylation ofNeprilysin 
Purified neprilysin (1.8 flg) was treated with 2.5 flg of 
N-hydroxysuccinimde-biotin in a 100 fll reaction containing 
100 mM HEPES buffer, pH 8, for the indicated times. An 
aliquot oflO fll (0.18 mg) was withdrawn and then subjected 
to SDS-PAGE, transferred to a PVDF membrane, and then 
treated with 1/2000 of avidin HRP, and visualized by 
enhanced chemiluminescense (ECL). Samples at 0, 1 and 2 
hrs contained 10 fll ofthereactionmixture, while the 4 and 18 
hr samples contained 5 fll. 
EXAMPLE 8 
Biotinylated Neprilysin Retains Activity 
Purified neprilysin treated with 2.5 mg ofN-hydroxysuc-
cinimde-biotin for the indicated time as in example 7 was 
assayed for neprilysin activity using glutaryl-Ala-Ala-Phe-
MNA (MNA=methoxynaphthylamide) as substrate. As 
shown in FIG. 10 about 75% of the activity relative to the 
a two-month old recipient mouse producing neprilysin 
expression on white blood cells. About 65% of the bone 
marrow white blood cells used for transplantation expressed 
neprilysin. Cells in the M1 region are neprilysin positive 
cells. Control is a histogram of a recipient mouse without 
bone marrow transplantation. There are less than 2% cells 
appearing as neprilysin positive cells. The panel labeled NEP 
60 untreated control was retained after 2 hrs. 
is a histogram of cells from a recipient mouse receiving 
NEP-lentivirus transduced bone marrow cells and shows 65 
greater than 20% of the white blood cells express neprilysin. 
The panel labeled NEPx is a histogram of cells from a recipi-
EXAMPLE 9 
Biotinylation oflsolated Red Blood Cells 
A 10% red blood cell suspension was treated with 75 f.LM 
N-hydroxysuccinimde-biotin at room temperature for 2 h in 
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phosphate buffered saline (PBS). After incubation, the red 
blood cell suspension was washed with PBS containing BSA 
at 2 mg/ml. FITC-streptavidin was used for FACS analysis. 
As shown in FIG. 11, Panel A is a control of untreated red 
blood cells. Panel B shows more than 75% of the red blood 5 
cells contained biotin. 
EXAMPLE 12 
24 
EXAMPLE 14 
Neprilysin Modified to be Bound to an Antibody 
FIG. 15. shows a schematic of neprilysin modified with a 
single chain antibody directed against a red blood cell epitope 
sequence linked to the C-terminus of the enzyme according to 
the methods provided and incorporated in their entirety by 
reference herein to Spitzer D, et a!., ScFv-mediated in vivo 
Coupling ofBiotinylated Neprilysin to Red Blood 
Cells 
10 targetingofDAF to erythrocytes inhibits lysis by complement. 
Mol Immunol. 2004 February; 40(13):911-9. This chimeric 
protein was shown to bind to mouse red blood cells. 
Although illustrative embodiments of the present invention 
have been described in detail, it is to be understood that the 
15 present invention is not limited to those precise embodiments, 
and that various changes and modifications can be effected 
therein by one skilled in the art without departing from the 
scope and spirit of the invention as defined by the appended 
claims. 
Twenty flg of biotinylated neprilysin (b-NEP) was incu-
bated with 5 fll of packed streptavidin-conjugated biotiny-
lated-red blood cells in 100 fll of PBS containing BSA at 2 
mg/ml at room temperature for 1 hr. After washing 5 times, 
the red blood cells were incubated with anti-neprilysinmono-
clonal antibody labeled with FITC conjugated anti-neprilysin 
antibody CD 1 OF) at room temperature for half an hour. The 
sample was then analyzed by FACS. Results in FIG. 12 show 20 
that biotinylated neprilysin can be linked to biotinylated red 
blood cells using streptavidin. 
EXAMPLE 13 
Modified Neprilysin 
Neprilysin was modified with a C-terminal human red 
blood cell binding peptide sequence linked to the C-terminus 
25 
of the enzyme. See FIG. 13. The red blood cell binding 30 
peptide is derived from a peptide sequence of the histidine 
rich protein from P. falciparum according to the methods 
provided and incorporated in their entirety by reference 
herein to Lopez R, Urquiza M, Curtidor H, Eduardo Caminos 
J, Mora H, Puentes A, Patarroyo M E. Plasmodium falci- 35 
parum: red blood cell binding studies of peptides derived 
from histidine-rich KAHRP-1, HRP-II and HRP-III proteins. 
Acta Trap. 2000 May 31; 75(3):349-59. 
FIG. 14 shows that modified neprilysin containing a C-ter-
minal human red blood cell binding peptide sequence as 40 
shown in example 13 is bound to human red blood cells. The 
construct shown in FIG. 13 was transiently expressed in HEK 
cells using a pCSC vector. A cell extract containing the modi-
fied NEP was prepared in PBS and incubated with human red 
blood cells isolated from 1 ml of human blood in 0.2 ml of 45 
PBS for 2 hrs at room temperature The sample was then 
centrifuged and the NEP activity in the supernatant deter-
mined withglutaryl-ala-ala-Phe-MNAas substrate. Although 
none of the uumodified NEP is depleted from the sample by 
red blood cells, -50% of the modified NEP is removed by 
binding to red blood cells. 
What is claimed is: 
1. A method for reducing amyloid peptide in the brain of a 
patient in need thereof, said method comprising: 
(a) generating a non-replicating recombinant viral vector 
comprising a nucleotide sequence encoding neprilysin 
operably linked to a promoter; 
(b) obtaining hematopoietic stem cells from the patient; 
(c) introducing the non-replicating recombinant viral vec-
tor into the hematopoietic stem cells ex vivo· and 
(d) introducing the hematopoietic stem ~ells of s;ep (c) into 
the patient via bone marrow transplantation or via intra-
venous injection, wherein the neprilysin is expressed in 
the peripheral blood on the surface of one or more of the 
hematopoietic cells at a sufficient level and duration to 
result in the efflux of A~ protein from the brain and 
facilitate degradation and clearance of A~ protein from 
the peripheral blood. 
2. The method according to claim 1 wherein the non-
replicating recombinant vector is a viral vector selected from 
the group consisting of adena-associated virus (AAV) vector, 
lentivirus, murine leukemia virus and herpes-simplex virus 
(HSV) vector. 
3. The method according to claim 1 wherein the hemato-
poietic cells are red blood cells, white blood cells, platelets or 
a combination of all. 
4. The method according to claim 3 wherein the hemato-
poietic cells are red blood cells. 
5. The method according to claim 1, wherein said A~ 
protein is A~ 1 _40 or A~ 1 _42 . 
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